MSLN CAR-T cells

MSLN CAR-T cells are a form of chimeric antigen receptor (CAR) T cell therapy engineered to target mesothelin (MSLN), a membrane-bound surface glycoprotein that is overexpressed in various solid tumors such as ovarian cancer, lung adenocarcinoma, and other malignancies. The therapy involves collecting a patient's own T lymphocytes and genetically modifying them ex vivo to express a synthetic receptor that specifically recognizes the MSLN antigen on tumor cell surfaces. Upon reinfusion into the patient, these modified T cells can selectively recognize and kill tumor cells expressing MSLN without requiring traditional antigen presentation pathways[1][2][4]. Several generations of MSLN-CAR constructs have been developed with different co-stimulatory domains (e.g., CD28 or 4-1BB) to optimize antitumor efficacy and persistence[1]. Some advanced versions also secrete anti-PD-1 antibodies to counteract immunosuppressive signals in the tumor microenvironment[2]. Preclinical studies have shown potent antitumor activity in models of ovarian cancer and other solid tumors; early-phase clinical trials indicate manageable safety profiles with some evidence of disease stabilization or partial remission in patients with advanced metastatic cancers[2][5].

Other names

mesothelin-targeted chimeric antigen receptor T cellsmesothelin-directed CAR T cells